Integra LifeSciences Reports Second Quarter 2024 Financial Results

Second quarter GAAP earnings per diluted share of $(0.16), compared to$0.05 in the prior year; adjusted earnings per diluted share of $0.63, compared to$0.71 in the prior year. Second quarter revenues of $418.2 million increased 9.7% on a reported basis and 2.3% on an organic basis compared to the prior year. Revenue increased 0.3% on an organic basis excluding Boston. Received PMA approvable notification pending GMP certification for SurgiMend. Second Quarter 2024 Consolidated Performance Adjusted EBITDA ...